Six months of treatment with GemVax & KAEL’s investigational GV1001 provided benefits in the cognition and daily life activities of adults with moderate to severe Alzheimer’s disease, who take Aricept (donepezil) for dementia, according to data from a Phase 2 clinical trial. The results were published in an article, “Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial,” in the journal…
You must be logged in to read/download the full post.
The post GV1001 Treatment Shows Promise for Moderate to Severe Alzheimer’s appeared first on BioNewsFeeds.